These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32506696)

  • 1. Dextran deposition in reticuloendothelial organs in hemodialysis patients: A forgotten adverse effect of low-molecular weight dextran.
    Yokokawa T; Ikura Y; Okabe H; Iwai Y
    Hemodial Int; 2020 Jul; 24(3):E46-E49. PubMed ID: 32506696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy.
    Palevsky PM; Burr R; Moreland L; Tokiwa Y; Greenberg A
    ASAIO J; 1995; 41(4):847-9. PubMed ID: 8589465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dextran-related complications in head and neck microsurgery: do the benefits outweigh the risks? A prospective randomized analysis.
    Disa JJ; Polvora VP; Pusic AL; Singh B; Cordeiro PG
    Plast Reconstr Surg; 2003 Nov; 112(6):1534-9. PubMed ID: 14578781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients.
    St Peter WL; Lambrecht LJ; Macres M
    Am J Kidney Dis; 1996 Oct; 28(4):523-8. PubMed ID: 8840941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dosage and elimination of Dextran 40 in patients on hemodialysis (author's transl)].
    Köhler H; Weihrauch TR; Fiegel P; Kirch W; Höffler D
    Klin Wochenschr; 1975 Jun; 53(11):523-7. PubMed ID: 1152343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dextran deposits in tissues of patients undergoing haemodialysis.
    Bergonzi G; Paties C; Vassallo G; Zangrandi A; Poisetti PG; Ballocchi S; Fontana F; Scarpioni L
    Nephrol Dial Transplant; 1990; 5(1):54-8. PubMed ID: 1691467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Case of acute kidney failure induced low-molecular weight dextran effectively treated by plasma exchange].
    Matsushima H; Yonemura K; Nakamura T; Takahashi M; Iketani N
    Nihon Naika Gakkai Zasshi; 1994 Feb; 83(2):294-5. PubMed ID: 7525804
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prevention of dialysis-induced leukopenia and hypoxemia by using low-molecular dextran].
    Wanic-Kossowska M
    Pol Arch Med Wewn; 1990 Jul; 84(1):16-22. PubMed ID: 1701247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dextran antibodies, complement conversion and circulating immune complexes after intravenous iron dextran therapy in dialysed patients.
    Fleming LW; Stewart WK; Parratt D
    Nephrol Dial Transplant; 1992; 7(1):35-9. PubMed ID: 1374865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iatrogenic generalized storage of dextran in patients on regular dialysis.
    Stejskalová A; Stejskal J; Elleder M
    Czech Med; 1987; 10(4):201-16. PubMed ID: 2449318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Overload histiocytosis in 2 hemodialyzed patients. Possible role of dextran 40].
    Babinet F; Simonin D; Kernaonet E; Duclos R; Lebon P
    Nephrologie; 1986; 7(1):19-23. PubMed ID: 2421175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of adequate hemodialysis access. Prevention of neointimal hyperplasia.
    Taber TE; Maikranz PS; Haag BW; Gaylord GM; Dilley RS; Ehrman KO; Brown PB; Nelson DR; Kay DC; Roberts TL
    ASAIO J; 1995; 41(4):842-6. PubMed ID: 8589464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute pulmonary edema associated with use of low-molecular weight dextran for prevention of microvascular thrombosis.
    Kitziger KJ; Sanders WE; Andrews CP
    J Hand Surg Am; 1990 Nov; 15(6):902-5. PubMed ID: 1702797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaphylactic reactions to high molecular weight dextran during hysteroscopic surgery.
    Huhn AM
    CRNA; 1995 Nov; 6(4):167-71. PubMed ID: 8680345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Left ventricular performance in chronic hemodialysis patients studied during intense exercise and during a dextran infusion test (author's transl)].
    Dongradi G; Kahn JC; Rocha P; Baron B; Moranne JB; Fendler JP
    Nephrologie; 1981; 2(2):73-6. PubMed ID: 6170005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of refractory hemodialysis ascites with maintenance peritoneal dialysis.
    Ing TS; Daugirdas JT; Popli S; Kheirbek AO; Humayun HM; Gandhi VC; Chapa SM
    Clin Nephrol; 1981 Apr; 15(4):198-202. PubMed ID: 7237867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaphylactoid reactions to Dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004.
    Zinderman CE; Landow L; Wise RP
    J Vasc Surg; 2006 May; 43(5):1004-9. PubMed ID: 16678697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Excessive tissue storage of colloids in the reticuloendothelial system].
    Ginz HF; Gottschall V; Schwarzkopf G; Walter K
    Anaesthesist; 1998 Apr; 47(4):330-4. PubMed ID: 9615850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low molecular weight dextran: a continuing cause of acute renal failure.
    Feest TG
    Br Med J; 1976 Nov; 2(6047):1300. PubMed ID: 1000202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.